Eribulin and Confusion: A Previously Unknown Drug Side-Effect

  • Abu Baker Sheikh Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA
  • Abhilash Perisetti Department of Gastroenterology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
  • Nismat Javed Department of Internal Medicine, Shifa College of Medicine, Islamabad, Pakistan
  • Rahul Shekhar Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA

Keywords

Eribulin, encephalopathy, breast cancer

Abstract

Eribulin is an antineoplastic agent used in advanced breast cancer refractory to anthracycline and taxane treatment regimens. A wide variety of side effects with unclear mechanisms have been noted, but encephalopathy has not been widely reported. Here we describe the case of a middle-aged woman treated with eribulin for advanced breast cancer who subsequently developed central nervous system drug-induced toxicity but improved promptly with steroid administration.

VIEW THE ENTIRE ARTICLE

References

  • Maeda S, Saimura M, Minami S, Kurashita K, Nishimura R, Kai Y, et al. Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Breast 2017;32:66–72.

  • Meattini I, Desideri I, Di Cataldo V, Francolini G, De Luca Cardillo C, Scotti V, et al. Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience. Future Oncol 2016;12:1117–1124.

  • Narayan S, Carlson EM, Cheng H, Condon K, Du H, Eckley S, et al. Novel second generation analogs of eribulin. Part III: Blood-brain barrier permeability and in vivo activity in a brain tumor model. Bioorg Med Chem Lett 2011;21:1639–1643.

  • Sirvén MB, Fernández-Ortega A, Stradella A, Morilla I, Falo C, Vázquez S, et al. Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center. BMC Pharmacol Toxicol 2019;20:68.

  • Catania G, Malaguti P, Gasparro S, Cognetti F, Vidiri A, Fabi A. Activity of eribulin mesylate in brain metastasis from breast cancer: a stone in a pond? Oncology 2018;94(Suppl 1):29–33.
  • Published: 2020-06-09

    Issue: Vol 7 No 9 (view)

    Section: Articles

    How to cite:
    1.
    Sheikh AB, Perisetti A, Javed N, Shekhar R. Eribulin and Confusion: A Previously Unknown Drug Side-Effect. EJCRIM [Internet]. 2020Jun.9 [cited 2020Sep.24];7(9). Available from: https://ejcrim.com/index.php/EJCRIM/article/view/1708